Lopinavir
Lopinavir structure
|
Common Name | Lopinavir | ||
|---|---|---|---|---|
| CAS Number | 192725-17-0 | Molecular Weight | 628.801 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 924.2±65.0 °C at 760 mmHg | |
| Molecular Formula | C37H48N4O5 | Melting Point | 124-127°C | |
| MSDS | Chinese USA | Flash Point | 512.7±34.3 °C | |
|
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Antimicrob. Agents Chemother. 42(12) , 3218-24, (1998) The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray crystal structure of the complex of HIV protease and ritonavir, t... |
|
|
HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
J. Antimicrob. Chemother. 70(1) , 243-8, (2015) PI susceptibility results from a complex interplay between protease and Gag proteins, with Gag showing wide variation across HIV-1 subtypes. We explored the impact of pre-treatment susceptibility on the outcome of lopinavir/ritonavir monotherapy.Treatment-nai... |
|
|
Antiretroviral therapy response among HIV-2 infected patients: a systematic review.
BMC Infect. Dis. 14 , 461, (2014) Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults.Data ... |